Nuevocor

Nuevocor, headquartered in Singapore, is a privately held preclinical biopharmaceutical company focused on developing adeno-associated virus (AAV)-based gene therapies for the treatment of inherited cardiomyopathies to address significant unmet clinical needs. Building on decades of research into the fundamental mechanisms of LMNA-related diseases, Nuevocor is concentrating its lead program on lamin A/C dilated cardiomyopathy (LMNA DCM) gene therapy.